



Biocidal Product Family Work in Progress

Camelia Mihai

Cefic – European Biocidal Products Forum (EBPF)

Biocides Stakeholders' Day

24 September 2014

Helsinki, Finland





Overall aim

- Facilitate access to the market by authorising a group of biocidal products as a Biocidal Product Family (BPF)
- Allow variations in composition without adversely affecting risk and efficacy of the Biocidal Products (BPs) belonging to a BPF
- Facilitate the placing on the market of new BPs within the ranges of the family, but not explicitly identified in the original authorisation
 - No notification needed for variation in composition of the pigments, perfumes and dyes (PPDs)
 - Notification process (30 days before placing on the market)



Legal frame

Article 3 (s)

‘biocidal product family’ means a group of biocidal products having:

- (i) similar uses;
- (ii) the same active substances (AS);
- (iii) similar composition with specified variations; and
- (iv) similar levels* of risk and efficacy;

*Article 19 (6):

- maximum risks to human health, animal health and the environment
- minimum level of efficacy

over the whole potential range of products within the biocidal product family



Legal frame

- All authorisation types are possible:
 - National Authorisation
 - Mutual Recognition
 - Union Authorisation
- Application of the Changes Regulation
- Application of the Same Biocidal Product Regulation
(needs further clarification)



Implementation

WORK IN PROGRESS





Implementation

WORK IN PROGRESS





Work in Progress

- A.I.S.E. & Cefic Workshop on March 10th, 2014
- Commission proposal (CA-March14-Doc.5.12¹)
 - information in a structured way: 3-level approach
 - *meta* SPC concept
- Discussions at Coordination Group meetings

¹ <https://circabc.europa.eu/w/browse/8e840f78-e5af-4880-939e-e2db50ef7b4c>

SPC - Summary of Product Characteristics



Administrative information

Name, Manufacturing address, Authorisation Number, Expiry date



Composition information

Active Substance + non-Active ingredients, classification, hazard and precautionary statements

Information linked to the use

Product type, Target organism(s), Field(s) of use, Application method(s)/rate(s), Category(ies) of users, Pack information, Instructions to use, Risk Mitigation Measures



3-level approach

Level 1 - Family

Level 2 – Subfamily
Meta SPC

**Level 3 – Individual
Biocidal Product**



3-level approach

Level 1 - Family



Authorisation Number (AN)

Level 2 - Subfamily *Meta SPC*



AN + *meta SPC* suffix

Level 3 - Individual Biocidal Product



AN + *meta SPC* suffix + BP suffix



3-level approach



Family - Level 1

- **Different classification**
- Composition range of the family (**AS ≠ 0**)
- Variation in the formulation type

meta SPC - Level 2

- **Same classification**
- Composition range of the sub-family (**AS ≠ 0**)
- PT variation possible
- Same set of H&P statements
- Same set of RMMs

Individual BP - Level 3

- H&P statements relevant to the individual product
- RMMs relevant to the individual product



Grouping products into Family



- Strictly within ranges (variations in terms of composition, product formulation, claim, use)
- A new product within the defined ranges may be notified

Remember

- Grouping will not always be possible
- Some products will not fit into the defined ranges



Dossier Assessment

- At the family level and where not possible at the meta SPC level?
- Maximum risk
- Minimum efficacy
- Flexible and case-by-case considerations will have to be allowed when discussing variations in the composition and the impact on the overall risk assessment and *meta* SPC grouping



Practical considerations



- Pre-submission meeting with the evaluating Member State
- Seek opportunities whereby it is avoided that the entire family application is jeopardised in case of a concern with an individual biocidal product or a *meta* SPC within that family
- For multi-PT (product type) combinations, deadline for applications for authorisation - same rules as established for single products¹

¹<https://circabc.europa.eu/sd/a/a51ecad8-187e-4be6-887c-8026f33bb8c5/CA-Sept13-Doc.6.2.b%20-%20Multi-PT%20products.doc>



Further work



- Development of guidance (Q&A?)
- Submission/authorisation tools:
 - SPC template for Families (level 1, 2, 3)
 - How to apply suffixes in practice
 - IT system (R4BP3)
- Risk assessment and evaluation of dossiers
- Dossier building (read – across between products)



Concluding thoughts...

- Encourages innovation by the development of products of “same or lower risk” and “minimum level of efficacy”
- Reduction of workload for both Member State and applicants for the same (more?) number of biocidal products

- Grouping the most relevant number of BPs - challenge

- Cost reduction?
- Biocide Product Family & “Same product” authorisation?

Thank you for your attention!




Table of Silence – Tg Jiu - Romania